Navigation Links
SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
Date:12/8/2011

es Litigation Reform Act of 1995.  These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," predict," "opportunity" and "should," among others.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, the response from the United States Food and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI >30 kg/m2), or overweight patients (BMI >27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the t
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
2. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
3. SequelMed EMR Version 8 Certified by Ohio Board of Pharmacy
4. Sequel Systems, Inc. Meaningful Use EHR Receives ONC-ATCB 2011/2012 Certification
5. Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology
6. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
7. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
10. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
11. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Research and Markets has ... Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to ... purposes of this report, the human microbiome market is segmented ... microbiome market is expected to be valued as $294 million ... of 22.3% within the forecast period of 2019-2023. The market ...
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... , Sept. 19, 2014  Alere Inc. (NYSE: ... issued the following statement today in support of President ... "As the global leader in rapid diagnostics ... a national strategy to address the serious threat of ... with the Administration on initiatives to promote the development ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... SEATTLE, April 27, 2011 Cell Therapeutics, Inc. ("CTI" ... accomplishments and financial results for the first quarter ended ... we raised $50 million through two financings, advanced pixantrone ... license from Chroma Therapeutics Ltd. ("Chroma") to co-develop and ...
... The Premier healthcare alliance, a network ... healthcare sites working together to achieve high quality, cost-effective ... leading provider of FDA-approved Superficial Radiotherapy committed to providing ... sufferers, a group purchasing agreement for the SRT-100™. Sensus ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 2Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 3Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 4Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 5Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 6Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy 2Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy 3
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 On ... News at the Platinum PR and Top Places to ... in New York City. Camino received honorable mentions in ... Campaign” — for its work elevating Latina voices in ... incredible organization and be a part of its efforts ...
(Date:9/19/2014)... 2014 According to a report from ... blood-thinner Xarelto, named as defendants in several lawsuits filed ... moved the court to dismiss those suits because the ... connection with Philadelphia.* The cases include, for instance, Fontan ... Pa. Comm. Pls., Philadelphia Cty.), which was brought by ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Although ... key health benefits, most middle-aged and older adults ... type of exercise, according to new research. ... the muscle-strengthening recommendations set by the Department of ... Strength is essential for promoting health and ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its ... health. This therapy has grown tremendously across USA in the ... safe and dependable. It has far reaching benefits for ageing ... a very healthy and active lifestyle even beyond their middle ... senior therapist at MetroMD said, “HGH or Human Growth hormones ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... , This release is available in Spanish ... when we talk about a disease? What affects the ideas ... the University of Granada have developed a test ... disease. This advance will enable the development of clinical psychological ...
... (SACRAMENTO, Calif.) A study of the options for ... been treated for precancerous cervical lesions found that an ... strategy. Joy Melnikow, professor in the Department of ... screening strategies for the 500,000 American women diagnosed and ...
... WASHINGTON, Oct. 20 -- Scientists and engineers from around the ... Rochester, N.Y. next week to discuss some of the latest ... science, the development of new materials, and medicine. Journalists ... -- the 94th annual meeting of the Optical Society (OSA), ...
... Reporter , WEDNESDAY, Oct. 20 (HealthDay News) -- Researchers have discovered ... levels: Regular consumption of the world,s two most popular beverages may ... In fact, the latest research suggests that those who drink as ... may lower brain cancer risk by as much as 34 percent. ...
... The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical ... Ridley-Thomas and Anne-Merelie Murrell, president of Giroux Glass Company, Inc., ... the Terranea Resort in Rancho Palos Verdes. Supervisor ... Excellence Award for Community Service. Mrs. Murrell will be ...
... Oct. 20 (HealthDay News) -- A combination of animal and ... therapy that could ultimately help in the treatment of major ... levels of a brain protein known as p11. The study ... of feelings of reward, pleasure and satisfaction with positive life ...
Cached Medicine News:Health News:The impact of chronic diseases on patients also depends on their perception of the disease 2Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 2Health News:Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 2Health News:Colorful brains, cooling lasers, disease-detecting lights and more 3Health News:Colorful brains, cooling lasers, disease-detecting lights and more 4Health News:Colorful brains, cooling lasers, disease-detecting lights and more 5Health News:Colorful brains, cooling lasers, disease-detecting lights and more 6Health News:Colorful brains, cooling lasers, disease-detecting lights and more 7Health News:Colorful brains, cooling lasers, disease-detecting lights and more 8Health News:Colorful brains, cooling lasers, disease-detecting lights and more 9Health News:Colorful brains, cooling lasers, disease-detecting lights and more 10Health News:Colorful brains, cooling lasers, disease-detecting lights and more 11Health News:Colorful brains, cooling lasers, disease-detecting lights and more 12Health News:Can Coffee, Tea Lower Brain Cancer Risk? 2Health News:Can Coffee, Tea Lower Brain Cancer Risk? 3Health News:LA BioMed honors 2 leaders 2Health News:Animal Study Explores Potential Gene Therapy for Depression 2Health News:Animal Study Explores Potential Gene Therapy for Depression 3
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: